GlassScriptPhysician profile
Susan Neese
NPI 1396820528
$5,318.29
in general payments reported to CMS, 2019-2025
40 companies · $1,313 in 2025
The $1,313 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,604 · 2020: $515 · 2021: $181 · 2022: $163 · 2023: $569 · 2024: $972 · 2025: $1,313.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,854.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,854.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $579.84 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $569.22 | 2020-2024 | Proclaim |
| Astrazeneca Pharmaceuticals LP | $555.78 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $388.35 | 2019-2025 | |
| Glaxosmithkline, LLC. | $379.30 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $361.39 | 2019-2025 | Repatha, Otezla, Evenity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.91 | 2019-2025 | Jardiance |
| Pfizer INC. | $299.45 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $190.87 | 2019-2025 | Spravato, Xarelto |
| Novartis Pharmaceuticals Corporation | $130.68 | 2019-2025 | |
| Otsuka America Pharmaceutical, INC. | $129.94 | 2019-2024 | Rexulti |
| Lundbeck LLC | $128.81 | 2023-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $119.16 | 2025 | Voquezna |
| Lilly USA, LLC | $105.47 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $88.37 | 2019-2020 |
Show all 39 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Neese listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.